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Application of the platinum-based chemotherapy for colorectal cancer is restricted due to its severe
cytotoxic effects. In this study we used synergistic strategies by combining ()-Epigallocatechin gallate
(EGCG) with cisplatin or oxaliplatin to minimize the ill effects of platinum-based therapy. MTS assay was
used to examine the effect of EGCG, cisplatin and oxaliplatin on the proliferation of human colorectal
cancer DLD-1 and HT-29 cells. Autophagic process was evaluated by detection of LC3-II protein, auto-
phagosome formation, and quantiﬁcation of Acidic Vesicular. Treatment of DLD-1 and HT-29 cells with
EGCG plus cisplatin or oxaliplatin showed a synergistic effect on inhibition of cell proliferation and in-
duction of cell death. EGCG enhanced the effect of cisplatin and oxaliplatin-induced autophagy in DLD-1
and HT-29 cells, as characterized by the accumulation of LC3-II protein, the increase of acidic vesicular
organelles (AVOs), and the formation of autophagosome. In addition, transfection of DLD-1 and HT-29
cells with siRNA against ATG genes reduced EGCG synergistic effect. Our ﬁndings suggest that
combining EGCG with cisplatin or oxaliplatin could potentiate the cytotoxicity of cisplatin and oxaliplatin
in colorectal cancer cells through autophagy related pathway.
© 2015 Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Colorectal cancer (CRC) is the second most prevalent cancer and
the third leading cause of cancer deaths worldwide (1). Globally
more than 1 million new cases were reported annually resulting in
about 500,000 deaths worldwide per year (2). Although surgical
resection currently remains the only curative treatment for CRC,
adjuvant chemotherapy after surgical resectionwas still needed for
most patients with metastasis to palliate symptoms and prolong
life (3). The platinum-based chemotherapy regimens are adopted
widely for treatment of CRC; however, further improvement has
been difﬁcult due to their serious adverse cytotoxic events. Oxali-
platin, a third-generation platinum analog, has evolved as one of: þ86 27 67812892.
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Although oxaliplatin is generally well tolerated, peripheral sensory
neuropathy occurs as an adverse effect of oxaliplatin and is the
most common dose-limiting factor for oxaliplatin treatment (4).
Despite recent advances in primary prevention, combined
chemotherapy with operation, the long-term survival rate of CRC
patients has not been substantially improved.
The mode of cytotoxic action of anticancer drugs often in-
volves the induction of several types of programmed cell death
(PCD). Apoptosis involves a trial of biochemical events in multi-
cellular organisms, leading to a variety of cellular morphological
changes and death (5). Autophagy, another type of PCD, is an
evolutionary conserved catabolic process involving the degrada-
tion of cytoplasmic constituents by lysosomal activity (6,7). Once
initiated, cytoplasmic constituents, including organelles, are ﬁrst
sequestered by a phagophore and subsequently form a double-
membraned autophagosome, which subsequently fuse with ly-
sosomes, where the cargo of the autophagosome is degraded by
lysosomal enzymes (8). Autophagy is characterized morphologi-
cally by the formation of microtubule-associated protein 1 lightacological Society. This is an open access article under the CC BY-NC-ND license
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vesicular organelles in the cytoplasm (9). In addition to the
physiological role of autophagy, accumulated evidence has shown
that this process is also involved in many pathological conditions,
including neurodegeneration, aging, infectious disease, and can-
cer (10). Although the molecular mechanism underlying auto-
phagy and apoptosis remains to be fully elucidated, autophagic
process may serve as an alternative to apoptosis to eliminate
transformed cells. Accumulating evidence also indicates that
various anticancer agents activate autophagy and autophagic cell
death (11). For example, treatment of oxaliplatin and bortezomib
induced autophagic cell death of human colorectal carcinoma
HCT116 cells (12).
Tea is one of the most widely consumed beverages in the
world. Both epidemiological, preclinical and laboratory studies
have positively shown an association of tea consumption with
lower risk for certain types of cancers (13). Among different
types of teas, the non-fermented green tea is of particular in-
terest and has been regarded as the most effective cancer pre-
ventive beverage. ()-Epigallocatechin gallate (EGCG), which is
the predominant polyphenolic catechin constituent in green tea,
has been recognized as an important chemopreventive agent and
as modulators of tumor cell response to chemotherapy to sup-
press the growth, invasion, metastasis and angiogenesis of
various cancer cells by arresting the cell cycle, inducing
apoptosis, targeting molecules relating to angiogenesis (VEGF,
etc), metastasis (MMP, etc) and many other cellular regulatory
pathways (14e16).
Numerous investigations have shown EGCG apoptotic effect on
various cancer cell lines, while the study on its autophagic function
is poor (17). Our hypothesis was that EGCG, cisplatin and oxaliplatin
would act synergistically to induce cell death in colorectal cancer
cell lines through interaction between apoptosis and autophagy.
Hence, we investigated the synergistic effect of combined chemo-
therapy by EGCG, cisplatin and oxaliplatin on the proliferation and
autophagy of colorectal cancer cells. Our data show that EGCG
potently potentiate the cytotoxicity of cisplatin and oxaliplatin in
human colorectal cancer DLD-1 and HT-29 cells. To clarify the
molecular mechanisms underlying these responses to the com-
bined therapy, the effects of different compounds on autophagy
were investigated. Our observations suggest that EGCG enhances
the cisplatin and oxaliplatin-induced autophagic death in colorectal
cancer cells.
2. Materials and methods
2.1. Cells, chemicals and reagents
The human colorectal adenocarcinoma (DLD-1 and HT-29) cells
were grown in Dulbecco's modiﬁed Eagle's medium (DMEM) sup-
plemented with 10% fetal calf serum (Hyclone), penicillin (100 IU/
ml), streptomycin (100 mg/ml) at 37 C in a humid atmosphere with
5% CO2. EGCG, cisplatin, oxaliplatin, 3-methyladenine (3-MA) were
purchased from SigmaeAldrich (St. Louis, MO, USA). Antibodies for
ATG 5, glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
microtubule-associated protein 1 light chain 3 A/B (LC3A/B) were
purchased from Cell Signaling Technology. The secondary anti-
bodies, horseradish peroxidase-conjugated goat anti-mouse IgG,
goat anti-rabbit IgG were purchased from SigmaeAldrich.
2.2. MTS and synergy analysis
Thecytotoxiceffectof thecompoundoncellswasdeterminedusing
the 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium salt (MTS) assay reagents, according tothe manufacturer's instructions (Promega). After compound
treatment, cells were incubated with MTS solution for 2 h and
submitted for absorbency measurement at 490 nm using an enzyme-
linked immunosorbent assay plate reader. All experiments were per-
formed 3 times. The potential synergistic or additive effects of EGCG,
cisplatin, and oxaliplatin were evaluated by MTS assay following the
protocols as described previously. The combination index (CI) and the
degree of interaction was evaluated by computer-based Calcusyn
software (version2.1, Biosoft). According to theCI theorem, CI values of
<1, ¼1, and >1 indicate synergism, additive effect, and antagonism,
respectively.
2.3. Detection and quantiﬁcation of acidic vesicular
Autophagy was detected by quantiﬁcation of acidic vesicular
organelles (AVOs), a marker of autophagy, according to published
protocol. The non-protonated monomeric form of AO emits green
ﬂuorescence and dim red in the cytoplasm and nucleolus, while the
acidic compartment (e.g. lysosomes or late endosomes) trapped AO
ﬂuoresces bright red or orange. The intensity of the red ﬂuores-
cence is proportional to the degree of acidity. Brieﬂy, cells were
stained with acridine orange (1 mg/ml) at 37 C for 15 min. After
loading, the cells were washed with PBS and immediately analyzed
using EPICS ﬂow cytometer.
2.4. Western blot analysis
Western blot analysis was performed as stated previously. The
protein concentration was determined by the Bradford assay
(Bio-Rad). Equal amounts of the protein were resolved by sodium
dodecyl sulfate (SDS)-polyacrylamide gels, transferred onto
nitrocellulose membranes and stained with primary antibodies
overnight at 4 C, followed by the secondary antibody for 1 h at
room temperature. Immunoreactive bands were visualized by
Super Signal West Pico Chemiluminescent Substrate (Thermo
Scientiﬁc). For loading control analysis, blots were stripped and
incubated with antibodies to GAPDH. Western results were
scanned and quantiﬁed using Image J software (http://rsb.info.
nih.gov/ij/).
2.5. Knockdown of ATG 5
Autophagy was blocked by knockdown of ATG 5 with ATG 5
siRNA. Cells were seeded into a 12 well plate with 1 ml medium
and incubated overnight. Medium without serum, containing
25 nM ATG 5 siRNA, or control siRNA was mixed with 5 ml
transfection reagent for 30 min at room temperature and then
added to the cells. The final volume was adjusted with medium
to 0.5 ml per well and the mixture was incubated for 48 h. Cells
were harvested and assays were carried out to evaluate ATG 5
content. Cell viability was assayed by MTS assay after 48 h in-
cubation with EGCG plus different concentration of cisplatin and
oxaliplatin.
2.6. Transmission electron microscopy
Electron microscopy was performed as described previously.
Brieﬂy, cell samples were washed three times with PBS, trypsi-
nized, and collected by centrifuging at 1000 g for 5 min. The cells
pellets were ﬁxed with 2.5% glutaraldehyde and stored at 4 C
overnight. For subsequent processing, the cells werewashed in PBS,
post-ﬁxed with 1% osmium tetroxide for 1 h at room temperature,
dehydrated stepwise with ethanol and embedded in Spurr's plastic
resin. Ultrathin sections were cut and then examined under JEM-
1230 electron microscope.
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Data were expressed as means ± SD for triplicate experiments.
Statistic differences between groups were determined by One-way
ANOVA with Bonferroni's multiple comparison-tests. P < 0.05 was
considered statistically signiﬁcant.
4. Results
4.1. Co-treatment with EGCG synergistically inhibits the survival of
human colorectal cancer cells
To examine the effect of EGCG, cisplatin and oxaliplatin on the
proliferation of human colorectal cancer cells, a cell viability assay
was performed. DLD-1 and HT-29 cells were exposed to various
concentrations of cisplatin, and oxaliplatin alone or in combined
with EGCG for 48 h. The 50% inhibitory concentration (IC50) value of
EGCG, cisplatin and oxaliplatinwere shown in Table 1. Fig.1 shows a
differential response of colorectal cancer DLD-1 and HT-29 cells to
different compounds. Cisplatin and oxaliplatin at the concentration
of 20 mM had slight inhibitory effect on cell viability. However, a
signiﬁcant, dose-dependent decrease in proliferation was observed
in the cells treated with 100 mM EGCG plus 20 mM cisplatin or
oxaliplatin (Fig. 1B). A combination of 100 mM EGCG with 20 mM
cisplatin caused 66.5% reduction in cell viability than did treatment
on cisplatin own. After 48 h co-treatment with 100 mM EGCG, the
number of viable cells in the 20 mM oxaliplatin group was 30.0% in
DLD-1 cells. Pretreatment with 3-MA, however, blocked the syn-
ergistic cytotoxic effect in DLD-1 and HT-29 cells. (Fig. 1B). To
further determine whether the inhibitory effects were synergistic,
we used the CalcuSyn software to determine the CI values to
ascertain synergism (CI < 1), antagonism (CI > 1) or additive effect
(CI ¼ 1). The CI values are presented in Table 2. The CI-effect plot
showed that CI values for the combination of EGCG with cisplatin
and oxaliplatin were all less than 1.0, indicating a synergistic anti-
proliferative effect. (Table 2).
4.2. Co-treatment with EGCG synergistically induces autophagy in
human colorectal cancer cells
Chemotherapy-induced inhibitory effect and cell cycle arrest is
usually prerequisite to the demise of cancer cells, which can be
mediated by either apoptotic or autophagic pathways. Previously
studies indicated that autophagy can both act as an inhibitor or
enabler of programmed cell death (11). To investigate whether the
synergistic effect of cell death caused by the co-treatment induces
autophagic cell death, we examined the conversion of LC3-I to LC3-
II, which serves as a marker of the accumulation of autophagic
vesicles and autophagic activity. As shown in Fig. 2A, EGCG treat-
ment alone resulted in a dose-dependent increased conversion of
the normal LC3-I to the autophagic LC3-II isoform in human colo-
rectal cancer DLD-1 cells. However, inhibition of PI3K (with 3-MA),
a well-known inhibitor of autophagic process, impaired EGCG-
mediated autophagy induction in DLD-1 cells (Fig. 2B). Following
co-treatment with EGCG plus cisplatin and oxaliplatin, the ratio ofTable 1
The inhibitory potentials of EGCG, cisplatin and oxaliplatin on the viability of DLD-1
and HT-29 cells.
Cells Compound/IC50(mM)
EGCG Cisplatin Oxaliplatin
DLD-1 196.4 30.5 32.2
HT-29 168.8 32.8 35.6LC3-II/GAPDH as well as the accumulation of LC3-II was increased
(Figs. 2C, D, F). Similar results were obtained by quantiﬁcation of
acidic vesicular organelles (AVOs), a marker of autophagy (Figs. 2E,
G). To further conﬁrm that combined-therapy induces autophagy in
DLD-1 and HT-29 cells, we used electron microscopy to measure
autophagosome formation. Transmission electron microscopy
analysis conﬁrmed that the structures of autophagic vacuoles were
largely detected in co-treatment group as compared to its mono-
therapy controls (Fig. 3). These results suggest that the cell death
caused by the combined treatment with EGCG and cisplatin or
oxaliplatin depends on autophagic cell death at least partially.
4.3. Inhibition of autophagy by knockdown of ATG 5 decreased the
EGCG-induced synergistic effect
To further investigate the role of autophagy in EGCG-induced
synergistic cytotoxicity, ATG5-speciﬁc siRNA was transfected into
DLD-1 and HT-29 cells. Cells were first incubated with ATG 5 (or
control) siRNA for 48 h, EGCG was added and cell viability was
assayed after 48 h incubation with 100 mM EGCG plus different
concentration of cisplatin and oxaliplatin. Transfection of siRNA
against ATG 5 signiﬁcantly decreased the EGCG-induced synergistic
effect with cisplatin from a decline in cell viability of 64.5% in the
absence of the ATG 5 siRNA to a decline of 42.3% in the presence of
ATG 5 siRNA in DLD-1 cells. The control siRNA had no effect on
EGCG toxicity. Both ATG 5 knockdown cell lines showed similar
responses to EGCG plus cisplatin and oxaliplatin treatment (Fig. 4).
These results further clearly indicate that inhibition of autophagy
diminishes DLD-1 and HT-29 cells to EGCG-induced synergistic
cytotoxicity.
5. Discussion
The experiments reported in this paper were performed in order
to provide a better understanding of the interactive effects of EGCG
with cisplatin or oxaliplatin on their therapeutic potential in hu-
man colorectal cancer DLD-1 and HT-29 cells.
Historically, consumption of green tea has been associated
with health beneﬁts against multiple diseases like cancer. As the
predominant polyphenolic catechin in green tea, EGCG has
demonstrated remarkable chemopreventive and chemothera-
peutic potential against various types of cancers, through inter-
fering and targeting different signaling pathways (18). For
example, EGCG could induce apoptosis in pancreatic carcinoma
cells, prompting the loss of mitochondrial membrane potential,
increasing reactive oxygen species (ROS) formation and cyto-
chrome C release, thereby activating caspase-dependent
apoptosis (19). And similar results were observed in human
colorectal cancer HT-29 cells through modulating AMP-activated
protein kinase (AMPK) pathways (20). The potential role of EGCG
in the regulation of autophagy has just recently been investi-
gated. The induction of autophagy is known to maintain cell
survival under various cellular stress by degradating injured, or
aged proteins and organelles and the subsequent recycling of
degraded products in eukaryotic cells. However, persistent acti-
vation of autophagy can lead to caspase-independent autophagic
cell death, characterized by the excessive depletion of cellular
organelles and essential proteins (21). Experiments performed in
hepatocellular carcinoma treated with oxaliplatin indicated that
autophagy contributes to the tolerance of oxaliplatin via reactive
oxygen species (ROS) modulation (22). Activation of autophagy in
caco-2 colorectal cancer cells treated with oxaliplatin can also act
as cytoprotective response via endoplasmic reticula (ER) stress
induced by ROS production (23). However, the role of autophagy
in oncogenesis and anticancer therapy is rather contradictory.
Fig. 1. DLD-1 and HT-29 cells undergo growth inhibition after co-treatment with EGCG plus cisplatin and oxaliplatin. (A) Photomicrographs of DLD-1 cells treated with different
compound. DLD-1 cells were treated with cisplatin (20 mM), oxaliplatin (20 mM) and EGCG (100 mM) alone, or both agents with or without 3-MA (5 mM). Photos were taken at 48 h
post-treatment (original magniﬁcation,  20). (B) Cell viability was measured by MTS assay after 48 h of different compound treatment in DLD-1 and HT29 cells. Data presented as
means ± SD of three independent experiments.
Table 2
The combination index (CI) values of EGCG, cisplatin and oxaliplatin at 50% inhibition in DLD-1 and HT-29 cells.
Cells Co-treatment CI values at IC50/EGCG concentration (mM)
25 50 100
DLD-1 EGCG + Cisplatin 0.887 ± 0.061 0.825 ± 0.058 0.791 ± 0.047
EGCG + Oxaliplatin 0.742 ± 0.065 0.714 ± 0.049 0.721 ± 0.063
HT-29 EGCG + Cisplatin 0.931 ± 0.044 0.863 ± 0.049 0.848 ± 0.087
EGCG + Oxaliplatin 0.811 ± 0.046 0.807 ± 0.053 0.783 ± 0.058
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Fig. 2. EGCG enhances the effect of cisplatin and oxaliplatin-induced autophagy. (AeD) DLD-1 cells were treated with EGCG alone (A) pre-treated with 5 mM 3-MA (B) or co-treated
with the 20 mM cisplatin (C) or co-treated with 20 mM oxaliplatin (D). After 48 h incubation, total protein extracts were harvested from cells, then was determined by western
blotting analysis. The total gray value of each band was determined using Image J. The ratio of LC3-II to GAPDH is presented below. Data shown were the mean ± SD of three
independent experiments. (E) Flow cytometry analysis for acridine orange staining in DLD-1 cells treated with different compounds. (F) HT-29 cells were treated with 100 mM EGCG
alone or co-treated with 20 mM cisplatin/oxaliplatin. After 48 h incubation, total protein extracts were harvested from cells, then was determined by western blotting analysis. (G)
Flow cytometry analysis for acridine orange staining in HT-29 cells treated with different compounds.
F. Hu et al. / Journal of Pharmacological Sciences 128 (2015) 27e34 31The anti-mitogenic and synergistic inhibitory effect of EGCG in
our study is associated with the induction of autophagy as evi-
denced by the up-regulation of LC3-II protein, increased forma-
tion of autophagic vacuoles, and accumulation of acidic vesicular
organelles, etc. These data are in line with previous studies
reporting that EGCG stimulated LC3-II production and autopha-
gosome formation by inducing high mobility group Box
1(HMGB1) aggregation and autophagic degradation in macro-
phages, thereby alleviating lethal systemic inﬂammation caused
by HMGB1 release (24). Treatment with EGCG could also regulate
ectopic lipid accumulation through increased formation of LC3-II
and autophagosomes in primary bovine aortic endothelial cells
by activation of calmodulin-dependent protein kinase b pathway
(25). The mechanism by which EGCG induces or regulates auto-
phagic pathway remains elusive. Previous study indicated that
EGCG can form aggregation spontaneously via oxidation reaction
which in turn conjugates to proteins either covalently or non-
covalently, thus enhancing autophagy-mediated protein degra-
dation (24). Emerging evidence has also suggested a potential
link between ROS regulation and autophagic process, because
agents capable of inducing (e.g. mitochondrial electron-
transport-chain inhibitors) or inhibiting (e.g. N-acetylcysteine)
ROS formation affected autophagic process in human embryonic
kidney HEK 293 cells and human ﬁbroblast HT 1080 cells (26, 27).
ROS are highly reactive oxygen free radicals or non-radicalmolecules that are generated by multiple mechanisms. Auto-
phagy has been reported regulated by ROS including O2 and
H2O2, and O2 is the major form participating in ROS-regulated
autophagy (28). Several conventional or natural compounds for
cancer treatment have been shown to cause intracellular ROS
generation. Sodium selenite, a conventional anti-cancer agent,
could lead to the loss of mitochondria membrane permeability
and selective autophagic-mediated mitochondria degradation
through increasing intracellular ROS formation in malignant gli-
oma cells (29). Platinum-based therapy and EGCG-mediated cell
death may also depend on the generation of ROS either directly
or indirectly (30). Previous study indicated that autophagy is
promoted by AMP activated protein kinase (AMPK), which can be
activated directly by EGCG treatment through the generation of
reactive oxygen species (ROS) (31). These ﬁnding further explain
the autophagic induction and synergistic inhibition effect in DLD-
1 and HT-29 cells observed in our experiment.
In summary, this study highlights the role of autophagy in EGCG
induced synergistic effect with cisplatin and oxaliplatin in DLD-1
and HT-26 cells. Consequently, induction of autophagy by EGCG
potentiates the cytotoxicity of cisplatin and oxaliplatin in colorectal
cancer cells through autophagy related pathway. As green tea is one
of the most widely consumed beverage across the globe, this may
offer a new strategy of cancer treatment based on the combination
of EGCG and conventional anticancer drugs.
Fig. 3. Electron microscopy analysis of autophagic vacuoles in DLD-1(A) and HT-29 cells (B) treated with different compounds. Representative electronmicroscopic images were
shown. The high magniﬁcation image showed autophagic vacuolar organelles contained electron dense material and degraded subcellular organelles.
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Fig. 4. Effect of ATG5 depletion on EGCG-induced synergistic cytotoxicity. Cells were transfected with control siRNA or siRNA against ATG5 and treated with 100 mM EGCG plus
different concentration of cisplatin and oxaliplatin for 48 h, and cell viability was examined. The data are expressed as the mean ± SD of results obtained from three independent
experiments. Depletion of ATG 5 reduced EGCG-induced cell death. In transfected cells, LC3 conversion from LC3-I to LC3-II also showed to be lower than that observed in
untransfected cells.
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